The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7)

Science

Volumn 272, Issue 5262, 1996, Pages 735-738

  Surprenant, A ^a   Rassendren, F ^a   Kawashima, E ^a   North, R A ^a   Buell, G ^a  

^a GLAXO INST FOR MOLECULAR BIOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; PURINE P2 RECEPTOR; PURINE P2X RECEPTOR; 3' O (4 BENZOYL)BENZOYLADENOSINE 5' TRIPHOSPHATE; 3'-O-(4-BENZOYL)BENZOYLADENOSINE 5'-TRIPHOSPHATE; COMPLEMENTARY DNA; DIVALENT CATION; DRUG DERIVATIVE; ION CHANNEL; PURINE P2X7 RECEPTOR;

ANTIGEN PRESENTING CELL; ARTICLE; BRAIN; CHANNEL GATING; CYTOLYSIS; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPTIC TRANSMISSION; AMINO ACID SEQUENCE; ANIMAL; CELL DEATH; CELL LINE; CHEMISTRY; ELECTRIC CONDUCTIVITY; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOLECULAR CLONING; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; PATCH CLAMP; PHYSIOLOGY;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CATIONS, DIVALENT; CELL DEATH; CELL LINE; CLONING, MOLECULAR; DNA, COMPLEMENTARY; ELECTRIC CONDUCTIVITY; HUMANS; ION CHANNELS; MICE; MOLECULAR SEQUENCE DATA; PATCH-CLAMP TECHNIQUES; RATS; RECEPTORS, PURINERGIC P2; TRANSFECTION;

EID: 0029665112     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.272.5262.735     Document Type: Article

References (32)

1. H P. Buisman et al , Proc. Natl. Acad. Sci U S.A. 85, 7988 (1988); A. Zambon et al., Cell. Immunol. 156, 458 (1994)
2. H P. Buisman et al , Proc. Natl. Acad. Sci U S.A. 85, 7988 (1988); A. Zambon et al., Cell. Immunol. 156, 458 (1994)
3. L. C Nuttle and G. R. Dubyak, J. Biol Chem 269, 13988 (1994).
4. D. K Blanchard et al., Blood 85, 3173 (1995); F. DiVirgilio, P Pizzo, P. Zanovello, V. Bronte, D Collavo, Immunol Today 11, 274 (1990); C. C. Liou C. M. Walsh, J D E. Young, ibid. 16, 194 (1995).
5. D. K Blanchard et al., Blood 85, 3173 (1995); F. DiVirgilio, P Pizzo, P. Zanovello, V. Bronte, D Collavo, Immunol Today 11, 274 (1990); C. C. Liou C. M. Walsh, J D E. Young, ibid. 16, 194 (1995).
6. D. K Blanchard et al., Blood 85, 3173 (1995); F. DiVirgilio, P Pizzo, P. Zanovello, V. Bronte, D Collavo, Immunol Today 11, 274 (1990); C. C. Liou C. M. Walsh, J D E. Young, ibid. 16, 194 (1995).
7. C. Kennedy and P Leff, Trends Pharmacol. Sci 16, 168 (1995), M. P. Abbracchio and G Burnstock, Pharmacol. Ther. 64, 445 (1995).
8. C. Kennedy and P Leff, Trends Pharmacol. Sci 16, 168 (1995), M. P. Abbracchio and G Burnstock, Pharmacol. Ther. 64, 445 (1995).
9. G. Collo et al., J. Neurosci 16, 2495 (1996); A. J. Brake, M. J. Wagenbach, D. Julius, Nature 371, 519 (1994); S. Valera et al., ibid , p. 516; C. Chen et al., ibid. 377, 428 (1995), C Lewis et al., ibid , p. 432.
10. G. Collo et al., J. Neurosci 16, 2495 (1996); A. J. Brake, M. J. Wagenbach, D. Julius, Nature 371, 519 (1994); S. Valera et al., ibid , p. 516; C. Chen et al., ibid. 377, 428 (1995), C Lewis et al., ibid , p. 432.
11. G. Collo et al., J. Neurosci 16, 2495 (1996); A. J. Brake, M. J. Wagenbach, D. Julius, Nature 371, 519 (1994); S. Valera et al., ibid , p. 516; C. Chen et al., ibid. 377, 428 (1995), C Lewis et al., ibid , p. 432.
12. G. Collo et al., J. Neurosci 16, 2495 (1996); A. J. Brake, M. J. Wagenbach, D. Julius, Nature 371, 519 (1994); S. Valera et al., ibid , p. 516; C. Chen et al., ibid. 377, 428 (1995), C Lewis et al., ibid , p. 432.
13. G. Collo et al., J. Neurosci 16, 2495 (1996); A. J. Brake, M. J. Wagenbach, D. Julius, Nature 371, 519 (1994); S. Valera et al., ibid , p. 516; C. Chen et al., ibid. 377, 428 (1995), C Lewis et al., ibid , p. 432.
14. G Buell, C Lewis, G. Collo, R A North, A Surprenant, EMBO J 15, 55 (1996).
15. 7(1-418).
16. A. Surprenant, G. Buell, R. A. North, Trends Neurosci. 18, 224 (1995).
17. + RNA of each sample that had been electrophoresed and transferred to nylon; hybridization was detected by chemiluminescence
18. 7 receptors and J774 cells, we constructed concentration-response curves in low divalent solution by recording currents in response to 1-s applications of agonist at 8-min intervals with normal external solution present for 6 min before each application. This protocol was necessary to prevent the development of sustained inward currents (see Figs. 3 and 4) Lipofectin was used for transfection as described (6).
19. 4- resulting from the addition of 100 μM Na-ATP to these solutions would be 3.7 μM, 5 1 μM, and 29 μM, respectively.
20. M. Murgia, S Hanau, P Pizzo, M. Rippa, F. DiVirgilio, J. Biol. Chem. 268, 8199 (1993).
21. revF/ RT)](20 + 140α)}/145. In order of size (Rg. 3C), X was cesium, methylamine, tris(hydroxymethyl)-aminomethane, tetraethylammonium, and N-methyl-D-glucamine The internal solution also contained 10 mM EGTA and 5 mM Hepes External solutions also contained 10 mM glucose and normal or low concentrations of divalent cations; pH was maintained at 7.3 with HCl, histidine, or Hepes as required, and the osmolarity of all solutions was 295 to 315.
22. R. J. Evans, J. Physiol. (London) 487, 193P (1995).
23. S. E Hickman, J El-Khoury, S Greenberg, I. Schieren, S C. Silverstein, Blood 84, 2452 (1994).
24. J S. Wiley, J R. Chen, M. B. Snook, G. P Jamieson, Br. J. Pharmacol 112, 946 (1994); T H. Steinberg, A S Newman, J. A. Swanson, S C. Silverstein, J. Biol. Chem. 262, 8884 (1987).
25. J S. Wiley, J R. Chen, M. B. Snook, G. P Jamieson, Br. J. Pharmacol 112, 946 (1994); T H. Steinberg, A S Newman, J. A. Swanson, S C. Silverstein, J. Biol. Chem. 262, 8884 (1987).
26. The induction and kinetics of this sustained current were the same for inward current at - 70 mV and for outward current at 50 mV (n = 3) Indeed, it did not require any current to flow during the first, conditioning agonist applications when BzATP was applied 4 to 12 times in normal divalent solution while the reversal potential was held (0 mV in NaCl or -90 mV in NMDG), the sustained current was still evoked by the subsequent application of BzATP when the low divalent solution was introduced and the holding potential was set to -70 mV (n = 3, A Surprenant et al., data not shown).
27. YO-PRO-1 (10 μM; Molecular Probes, Eugene, OR) was added to the superfusion fluid during electrophysiological recordings 3 to 6 min before switching to low divalent solution and washed out upon switching back to normal divalent solution, after which the fluorescent lamp was turned on and cells were examined with a fluorescein isothiocyanate filter. For cell counts, 500 cells per cover slip were counted in each case.
28. R. J. Evans et at., Mol Pharmacol. 48, 178 (1995)
29. A. Surprenant et al., data not shown.
30. D. W Choi, Neuron 1, 623 (1988)
31. Abbreviations for the amino acid residues are as follows. A, Ala; C, Cys, D, Asp; E, Glu, F, Phe, G, Gly; H, His; I, Ile; K, Lys, L, Leu; M, Met; N, Asn, P, Pro; Q, Gin, R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
32. 2 cDNA and M J Solazzo for sequencing We are indebted to D Estoppey for cell culture, transfections, and generating stable cell lines.